ZA985376B - Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals - Google Patents

Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals

Info

Publication number
ZA985376B
ZA985376B ZA985376A ZA985376A ZA985376B ZA 985376 B ZA985376 B ZA 985376B ZA 985376 A ZA985376 A ZA 985376A ZA 985376 A ZA985376 A ZA 985376A ZA 985376 B ZA985376 B ZA 985376B
Authority
ZA
South Africa
Prior art keywords
dismutation
superoxide radicals
synthetic catalysts
analgesic methods
analgesic
Prior art date
Application number
ZA985376A
Other languages
English (en)
Inventor
Daniela Salvemini
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of ZA985376B publication Critical patent/ZA985376B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
ZA985376A 1997-06-20 1998-06-19 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals ZA985376B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5040297P 1997-06-20 1997-06-20

Publications (1)

Publication Number Publication Date
ZA985376B true ZA985376B (en) 1999-06-21

Family

ID=21965044

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA985376A ZA985376B (en) 1997-06-20 1998-06-19 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals

Country Status (12)

Country Link
US (2) US6180620B1 (enExample)
EP (1) EP1001752B1 (enExample)
JP (1) JP2002506445A (enExample)
AT (1) ATE256467T1 (enExample)
AU (1) AU733415B2 (enExample)
CA (1) CA2294155A1 (enExample)
DE (1) DE69820633T2 (enExample)
DK (1) DK1001752T3 (enExample)
ES (1) ES2215305T3 (enExample)
PT (1) PT1001752E (enExample)
WO (1) WO1998058636A1 (enExample)
ZA (1) ZA985376B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US20060270639A1 (en) * 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US20050171198A1 (en) * 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
CA2309154C (en) 1997-11-03 2010-02-16 Duke University Substituted porphyrins
ATE552260T1 (de) * 1999-01-25 2012-04-15 Nat Jewish Health Substituierte porphyrine und deren therapeutische verwendung
AU5048400A (en) 1999-05-27 2000-12-18 Monsanto Company Biomaterials modified with superoxide dismutase mimics
US20030069281A1 (en) * 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
US20050175580A1 (en) * 2001-01-05 2005-08-11 Daniela Salvemini Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
ATE439134T1 (de) * 2001-01-19 2009-08-15 Nat Jewish Med & Res Center Medikament zum schutz in der radiotherapie
WO2002058686A2 (en) * 2001-01-26 2002-08-01 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
EP1405066B1 (en) * 2001-03-02 2015-06-17 Galera Therapeutics LLC Chromatography of metal complexes
US20040137638A1 (en) * 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
AU2002312194B8 (en) * 2001-06-01 2008-05-15 Aeolus Sciences, Inc. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
AU2002315001A1 (en) * 2001-06-08 2002-12-23 Metaphore Pharmaceuticals, Inc. Libraries of conformationally constrained peptides, chiral azacrowns, and peptidomimetics and methods of making the same
JP2005519852A (ja) * 2001-06-26 2005-07-07 メタファー・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患の予防および／または処置のためのＳＯＤｍとコルチコステロイドの組合せ療養
WO2003039561A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
PT1463563E (pt) * 2001-12-14 2009-03-19 Alcon Inc Miméticos de dismutase do superóxido para o tratamento de distúrbios e doenças oculares
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
EP1513537A4 (en) * 2002-06-07 2006-09-06 Univ Duke Substituted porphyrins
US20030232784A1 (en) * 2002-06-14 2003-12-18 Benedict James J. Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain
CA2397684A1 (en) * 2002-08-12 2004-02-12 Michael P. Murphy Mitochondrially targeted antioxidants
CA2499994C (en) * 2002-09-23 2012-07-10 Verion, Inc. Abuse-resistant pharmaceutical compositions
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
CN1717234A (zh) * 2002-12-06 2006-01-04 爱尔康公司 用于治疗眼紊乱和疾病的超氧化物岐化酶模拟物
KR100648618B1 (ko) * 2003-11-19 2006-11-23 주식회사 웰스킨 활성 산소 억제제
KR20060101501A (ko) * 2003-12-11 2006-09-25 알콘, 인코퍼레이티드 시신경 및 망막 손상의 치료를 위한 슈퍼옥사이드디스무타제 유사체
US20120301403A1 (en) 2007-06-21 2012-11-29 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
US8217166B2 (en) * 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006069326A2 (en) * 2004-12-21 2006-06-29 Metaphore Pharmaceuticals, Inc. Polyethylene glycolated superoxide dismutase mimetics
KR100724586B1 (ko) 2005-12-09 2007-06-04 세종대학교산학협력단 수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물
EP2056675B1 (en) * 2006-10-12 2019-01-09 Galera Labs, LLC Methods of treating oral mucositis
WO2009065059A2 (en) 2007-11-14 2009-05-22 Kereos, Inc. Super-oxide dismutase mimetics
ES2530462T3 (es) 2008-05-22 2015-03-03 Galera Therapeutics Llc Combinación terapia antitumoral
EP2732817B1 (en) 2008-05-23 2016-08-24 National Jewish Health A compound for use in treating injury associated with exposure to phosgene or chlorine gas
WO2013048965A1 (en) 2011-09-26 2013-04-04 Galera Therapeutics, Llc Methods for treatment of diseases
UA126788C2 (uk) 2015-08-11 2023-02-08 Ґалера Лебз, Елелсі Комплексні сполуки, що містять макроциклічне кільце пентаази, які мають пероральну біодоступність
US12220420B2 (en) 2016-05-03 2025-02-11 Galera Labs, Llc Combination therapy for cancer treatment
AU2017318718B2 (en) 2016-09-01 2023-06-29 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
CA3053779A1 (en) 2017-02-15 2018-08-23 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local intestinal delivery
US11246950B2 (en) 2017-04-13 2022-02-15 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
AU2019215032A1 (en) 2018-01-31 2020-09-10 Board Of Regents Of The University Of Texas System Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
WO2021163397A1 (en) 2020-02-13 2021-08-19 Teva Pharmaceuticals International Gmbh Solid state forms of avasopasem manganese and process for preparation thereof
WO2025024390A2 (en) * 2023-07-21 2025-01-30 Galera Labs, Llc Carcinogenesis reduction with pentaaza macrocyclic ring complex

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751496B2 (ja) 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
US4999347A (en) 1986-08-28 1991-03-12 Sorenson John R J Analgesic method
US5216021A (en) 1986-08-28 1993-06-01 Sorenson John R J Analgesic method
JPS63313581A (ja) * 1987-06-16 1988-12-21 Ube Ind Ltd 修飾ス−パ−オキシドジスムタ−ゼ
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
DE69224839T2 (de) 1991-07-19 1998-10-08 Monsanto Co Mangan-Komplexe mit Stickstoff enthaltenden makrozyklischen Liganden, wirksam als Superoxiddismutasekatalysatoren.
CN1088086A (zh) * 1992-12-14 1994-06-22 西北大学 一种新型的护肤保健品
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
IL125889A0 (en) 1996-03-13 1999-04-11 Monsanto Co Bioconjugates of manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Also Published As

Publication number Publication date
AU733415B2 (en) 2001-05-17
ATE256467T1 (de) 2004-01-15
DK1001752T3 (da) 2004-04-19
DE69820633D1 (de) 2004-01-29
DE69820633T2 (de) 2004-09-23
CA2294155A1 (en) 1998-12-30
WO1998058636A1 (en) 1998-12-30
AU8068598A (en) 1999-01-04
EP1001752A1 (en) 2000-05-24
EP1001752B1 (en) 2003-12-17
US6395725B1 (en) 2002-05-28
ES2215305T3 (es) 2004-10-01
PT1001752E (pt) 2004-05-31
JP2002506445A (ja) 2002-02-26
US6180620B1 (en) 2001-01-30

Similar Documents

Publication Publication Date Title
ZA985376B (en) Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
GB2333453A (en) Colostrinin and uses thereof
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
GB9907461D0 (en) Neurite regeneration
ZA956709B (en) Ionene polymers containing biologically-active anions
AU2001249574A1 (en) Nitrogen reduction wastewater treatment system
PT946175E (pt) Utilizacao de uma combinacao de inibidores de h+, k+ -atpase e de glucocorticiodes no tratamento de polipos nasais
AU121935S (en) Fully retractable captive screw
GB2349422B (en) Common rail injector
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
EP1278520A4 (en) DIARYL PIPERIDYL-PYRROLE DERIVATIVES AS AN ANTIPROTOZENE AGENT
IL131478A0 (en) Methods for treatment of scar tissue
AU2003283055A8 (en) Opioid-receptor antagonists in transdermal systems having buprenorphine
PT1212119E (pt) Utilizacao de ciamemazina no tratamento do desmame subito de benzodiazepinas
IL139303A0 (en) Treatment of arthritis and other similar conditions
IL134479A (en) Transdermal therapeutic system with protection against oral use
DE50002304D1 (en) Tyrosin- und tryptophanhaltige peptide als antioxidantien
AU6091299A (en) Treatment device, treatment bed to be used therein and the use thereof
IT1284689B1 (it) Serratura, con dispositivo di sicurezza per abilitare l'introduzione della chiave nella serrtura.
SG90720A1 (en) Photoresist compositions with cyclic olefin polymers and additive
GB2371600B (en) Device for the purpose of improving the injection sequence in fuel-injection systems
IT1303455B1 (it) Attrezzatura per autocarri con cassone carrabile-scarrabile eribaltabile.
AU3202395A (en) Use of the combination of chlorpromazine plus interleukin-6 to treat or prevent septic shock
PT1017377E (pt) Utilizacao de 2-aminotetralinas 6,7-substituidas para o tratamento de condicoes inflamatorias mediadas por citoquina
UA26946C2 (uk) Аhтигістаміhhий лікарський препарат